The combination of inactivated and subunit vaccines enhances protective efficacy against Mycoplasma synoviae.

Mycoplasma synoviae (MS) infection predominantly manifests as lower respiratory symptoms but also leads to reduced egg production and increased culling rates in laying hens, causing significant economic losses throughout the production cycle. Vaccination remains the most cost-effective strategy to protect layers from MS infection. Previous studies from our laboratory identified and screened immunogenic proteins of MS, culminating in the development of a subunit vaccine that provided robust protection with a two-dose immunization.

Target antigen screening and development of a multi-component subunit vaccine against in chickens.

Introduction: (MS) is a globally important avian pathogen causing infectious synovitis and respiratory diseases in poultry, leading to significant economic losses. Despite advances in vaccine development, a commercially viable subunit vaccine against MS remains elusive.

Methods: We sequenced whole genomes of six clinical MS strains isolated from different Chinese provinces.

Identification of a surface protective antigen, MAP of Streptococcus equi subspecies zooepidemicus.

Streptococcus equi subspecies zooepidemicus (SEZ) is a zoonotic pathogen with adhesive and invasive properties. Due to the shortcomings of antibiotics and traditional inactivated vaccine, identifying protective antigens against SEZ would be helpful to the development of novel vaccines. MAP has been identified as a membrane anchored protein with a typical LPXTG-like cell wall-anchored motif.

Identification and characterization of a novel protective antigen, Sec_205 of Streptococcus equi ssp. Zooepidemicus.

Streptococcus equi ssp. zooepidemicus (SEZ) is an important pathogen of swine streptococcal diseases and can infect a wide range of animals as well as human beings. The absence of effective vaccine confounds the control of SEZ infection.